Kidney Disease Clinical Trial
Official title:
Validation of Fast Methods to Measure Glomerular Filtration Rate
This study will test the accuracy of a new "Fast GFR" (glomerular filtration rate) test to
evaluate kidney function. Accurate assessment of kidney function is important in many
clinical situations, including detecting kidney disease early, determining appropriate drug
dosages, deciding when to begin dialysis, and evaluating heart and kidney organ donors and
recipients. The current GFR test is used mostly for research purposes, as it is too costly
and complicated for general medical use. Another significant drawback to its use in
diagnosing acute kidney failure is the time it takes (3 to 24 hours) to complete, since
effective therapy for this condition requires its detection as soon as possible. The Fast
GFR, by comparison, takes only 45 minutes.
Patients 6 years old and older with kidney disease or with impaired kidney function caused
by abnormal heart function or swelling-from congestive heart failure, severe infections,
swelling from fluid accumulation, fluid in the abdomen, or burns-may be eligible for this
study. Patients will undergo both the standard and the Fast GFR tests, described below, to
evaluate the accuracy of the new test.
Fast GFR: Two catheters (thin flexible tubes) are placed into two arm veins, one for
injecting iothalamate-an agent commonly used in CT scanning and blood vessel imaging-and the
other for collecting blood samples. Baseline blood and urine samples are collected and then
0.5 milliliter (ml) iothalamate is injected into a vein. Blood samples are collected at 5,
10, 15, 20, 30, and 45 minutes in adults and at 5, 15, and 45 minutes in children. Urine is
collected at 45 minutes. The size of the bladder is measured using ultrasound to determine
if the bladder has completely emptied.
Standard GFR: Iothalamate (1 ml) is injected under the skin. Blood samples are collected at
60, 90, 120, 180 and 240 minutes. (A heparin lock is used to avoid multiple needle sticks.)
Urine is collected at 60, 90, 120, 180 and 240 minutes. The size of the bladder is measured
using ultrasound to determine if the bladder has completely emptied.
| Status | Completed |
| Enrollment | 150 |
| Est. completion date | June 2002 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | N/A and older |
| Eligibility |
INCLUSION CRITERIA: Both male and female subjects will be recruited without regard to race or ethnic origin. Suspected renal dysfunction based upon: Acute renal failure with elevated serum creatinine (at least 50% increase within 24 hours preceding enrollment) without stabilization or recovery, despite optimization of hemodynamic fluid status and correction of any known pharmacologic, pre-renal, or post-renal etiologic factors, or Congestive heart failure by clinical criteria (rales, S3, pedal edema on clinical exam), or Edema or ascites (by clinical exam), or Sepsis or septic physiology (shock or hyperdynamic circulation, suspected sepsis), or Chronic Renal Failure (creatinine greater than 1.3). Patients older than 18 years old who provide their own informed consent. Patients younger than 18 but at least 6 years old whose parent or legal guardian can provide informed consent. EXCLUSION CRITERIA: Inability to cooperate with the study. Known allergy to iothalamate or other iodine containing compounds. Urinary tract obstruction. Pregnant women or lactating mothers. Patients in whom vascular access cannot be secured. |
N/A
| Country | Name | City | State |
|---|---|---|---|
| United States | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Bethesda | Maryland |
| Lead Sponsor | Collaborator |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Coresh J, Toto RD, Kirk KA, Whelton PK, Massry S, Jones C, Agodoa L, Van Lente F. Creatinine clearance as a measure of GFR in screenees for the African-American Study of Kidney Disease and Hypertension pilot study. Am J Kidney Dis. 1998 Jul;32(1):32-42. — View Citation
Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, Molitch ME, Mitch WE, Siebert C, Hall PM, et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol. 1993 Nov;4(5):1159-71. — View Citation
Perrone RD, Steinman TI, Beck GJ, Skibinski CI, Royal HD, Lawlor M, Hunsicker LG. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis. 1990 Sep;16(3):224-35. — View Citation
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02369354 -
Transplant Social Worker Support for Live Kidney Donation in African Americans
|
N/A | |
| Not yet recruiting |
NCT02225782 -
Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function
|
Phase 4 | |
| Completed |
NCT00499187 -
Fanconi Syndrome Due to ARVs in HIV-Infected Persons
|
Phase 4 | |
| Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
| Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
| Completed |
NCT00183248 -
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00001835 -
Oxaliplatin in Cancer Patients With Impaired Kidney Function
|
Phase 1 | |
| Completed |
NCT01331941 -
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
|
Phase 1 | |
| Terminated |
NCT00436748 -
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
|
Phase 3 | |
| Completed |
NCT01467466 -
Prevention of Serious Adverse Events Following Angiography
|
Phase 3 | |
| Completed |
NCT01235936 -
Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
|
Phase 2 | |
| Completed |
NCT01974999 -
A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study
|
||
| Completed |
NCT01947829 -
Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)
|
N/A | |
| Recruiting |
NCT01240564 -
The Nephrotic Syndrome Study Network (NEPTUNE)
|
N/A | |
| Active, not recruiting |
NCT01228903 -
Uric Acid and the Endothelium is CKD
|
N/A | |
| Completed |
NCT00734357 -
Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients
|
N/A | |
| Completed |
NCT00781417 -
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease
|
N/A | |
| Completed |
NCT00093977 -
Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease
|
Phase 3 | |
| Completed |
NCT00185159 -
Olmesartan Medoxomil in Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT00096915 -
Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
|
Phase 3 |